Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11595081 | 0.82 | MMP1 (0.30) | — | |
| SCHEMBL28000108 | 0.82 | PSEN1 (0.31) | — | |
| SCHEMBL10060475 | 0.82 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL3189814 | 0.79 | TP53 (0.34) | ALDH1A1 | |
| SCHEMBL17290670 | 0.77 | — | — | |
| SCHEMBL514631 | 0.76 | NPC1 (0.37) | ALDH1A1 | |
| SCHEMBL10060466 | 0.75 | CA12 (0.46) | — | |
| SCHEMBL778854 | 0.75 | HTR6 (0.50) | ALDH1A1 | |
| SCHEMBL4315277 | 0.74 | LMNA (0.31) | — | |
| SCHEMBL178444 | 0.73 | GAA (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023185920-A1 | FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BERRYBIO (SHANGHAI) LIMITED (CN) | 2023-10-05 | — | — | WO | claimed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | claimed |
| WO-2022015938-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | claimed |
| CN-109912655-A | Alk protein degradation agent and its antitumor application thereof | 上海科技大学 | 2019-06-21 | — | — | CN | claimed |
| CN-107074866-B | Pyrimido-pyrrole compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2019-06-07 | — | — | CN | claimed |
| CN-107074866-A | Pyrimido-pyrrole compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2017-08-18 | — | — | CN | claimed |
| CN-106188060-A | Pyrimido azoles, its preparation method, Pharmaceutical composition and application thereof | 厦门大学 | 2016-12-07 | — | — | CN | claimed |
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | claimed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | claimed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | claimed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | claimed |
| EP-1817032-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | claimed |
| US-20060287303-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-12-21 | — | — | US | claimed |
| WO-2006058294-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | claimed |
| WO-2023185920-A1 | FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BERRYBIO (SHANGHAI) LIMITED (CN) | 2023-10-05 | — | — | WO | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| CN-116514722-A | Benzimidazole derivatives as modulators of retinoic acid related orphan receptor gamma (ROR gamma) and pharmaceutical uses thereof | 江苏恒瑞医药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | ALDH1A1 769/4885 |
| US-20060287303-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | ALDH1A1 2356/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.